NCT05949619View on ClinicalTrials.gov

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BL-M02D1

Administration by intravenous infusion

Trial Locations (1)

Unknown

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter